Physician profile
Michael E Blocker
NPI 1174586747
$5,999.41
in general payments reported to CMS, 2019-2025
18 companies · $928 in 2025
The $928 reported for 2025 was more than what 77% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $752 · 2021: $380 · 2022: $660 · 2023: $712 · 2024: $1,585 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,214.07 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,746.39 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,020.39 | 2019-2025 | |
| Janssen Biotech, INC. | $510.06 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $508.30 | 2019-2025 | Pifeltro, Delstrigo, Zerbaxa |
| Paratek Pharmaceuticals, INC. | $468.06 | 2019-2023 | Nuzyra |
| Abbvie INC. | $429.95 | 2019-2025 | Avycaz, Teflaro |
| Insmed, INC. | $402.20 | 2019-2025 | Arikayce |
| Astellas Pharma US INC | $195.51 | 2019-2025 | Cresemba, Veozah |
| Allergan, INC. | $192.60 | 2019-2020 | |
| Theratechnologies INC. | $169.43 | 2020-2024 | Trogarzo, Egrifta |
| Tetraphase Pharmaceuticals, INC. | $83.70 | 2019-2020 | |
| Shionogi INC | $71.59 | 2021-2024 | Fetroja |
| Melinta Therapeutics, LLC | $62.70 | 2020-2025 | Rezzayo |
| La Jolla Pharmaceutical Company | $48.32 | 2020-2024 | Xacduro, Xerava |
| Aimmune Therapeutics, INC. | $39.66 | 2025 | Zenpep |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $22.50 | 2019 | |
| Vyera Pharmaceuticals, LLC | $15.13 | 2019 | |
| Nabriva Therapeutics, Plc | $12.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Blocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.